Screener
Allogene Therapeutics ALLO Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deposit placed in escrow | — | 23,479 |
| Restricted cash | 10,292 | 10,292 |
| Other long-term assets | 3,531 | 3,615 |
| Total assets | $395,958 | $415,905 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,933 | $4,270 |
| Accrued and other current liabilities | 23,397 | 28,244 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's total assets?
- Allogene Therapeutics (ALLO) reported total assets of $395.96M in Q1 2026.
- How has Allogene Therapeutics's total assets changed year-over-year?
- Allogene Therapeutics's total assets decreased by 22.1% year-over-year, from $507.98M to $395.96M.
- What is the long-term trend for Allogene Therapeutics's total assets?
- Over 5 years (2020 to 2025), Allogene Therapeutics's total assets has grown at a -19.5% compound annual growth rate (CAGR), from $1.23B to $415.91M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Allogene Therapeutics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude